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Available online at www.sciencedirect.comRhabdomyolysis is a clinical condition of potential life
threatening destruction of skeletal muscle caused by diverse
mechanisms including drugs and toxins. Given the fact that
structurally not related compounds cause an identical
phenotype pinpoints to common targets or pathways,
responsible for executing rhabdomyolysis. A drop in
myoplasmic ATP paralleled with sustained elevations in
cytosolic Ca2+ concentration represents a common signature
of rhabdomyolysis. Interestingly, cardiac tissue is hardly
affected or only secondary, as a consequence of imbalance in
electrolytes or acid–base equilibrium.This dogma is now
impaired by compounds, which show up with combined
toxicity in heart and skeletal muscle. In this review, cases of
rhabdomyolysis with novel recently approved drugs will be
explored for new target mechanisms in the light of previously
described pathomechanisms.
Address
Medical University of Vienna, Center for Physiology and Pharmacology,
Institute of Pharmacology, Wa¨hringerstrasse 13A, A-1090 Vienna,
Austria
Corresponding author: Hohenegger, Martin
(martin.hohenegger@meduniwien.ac.at)
Current Opinion in Pharmacology 2012, 12:335–339
This review comes from a themed issue on
Musculoskeletal
Edited by Martin Hohenegger
Available online 5th May 2012
1471-4892     
# 2012 Elsevier Ltd. 
http://dx.doi.org/10.1016/j.coph.2012.04.002
Introduction
Luckily, rhabdomyolysis is a rare event of rapid destruc-
tion of skeletal muscle cells. The range of trigger mech-
anisms is wide and span from mechanical injury,
ischemia, infections, genetic alterations to drugs and
toxins. Excellent reviews exist on the various aspects
of rhabdomyolysis [1,2,3,4]. Here, I will concentrate
on recently approved drugs that have been associated
with clinical cases of rhabdomyolysis.
Currently, no algorithm exists that would predict a
patients risk to develop rhabdomyolysis. The only
manoeuvre to prevent skeletal muscle destruction
represents avoidance of a drug in individuals that already
suffered from rhabdomyolysis by this particular drug.
Open access under CC BY-NC-ND license. www.sciencedirect.com Statins are the only class of drugs that commonly lead
to skeletal muscle injury, in particular when combined
with drugs interacting on the level of pharmacokinetics.
However, an excellent review on the mechanisms behind
statins myotoxicity already exists in this journal [5].
Generally, symptoms of myalgia and muscle weakness
precede rhabdomyolysis. However, no laboratory
parameters are available that might help to estimate a
patients risk for the development of further muscle
injury. Slight cases of rhabdomyolysis might exist that
are subclinical, but still show up elevations of serum
creatine kinase (CK). The ill defined conditions of myal-
gia and myopathy are often seen by clinicians, but only a
very small number of these patients exacerbate rhabdo-
myolysis. Once skeletal muscle injury exceeds 100 g,
myoglobin is massively released and detectable before
CK raises [2]. Consequently, myoglobinuria, elevated
CK and serum potassium levels, hyperuricosuria and
acidosis come along with the progression of tissue
destruction. Conversely, the decline of these parameters
may also serve as control of recovery and therapeutic
success [1,2,3,4]. Leakage of the muscle protein myo-
globin into the urine plugs the kidney in particular under
acidic conditions. Thus, extensive and early fluid resus-
citation is crucial to stabilize circulation, buffer acidosis
and control serum potassium. Moreover, suggested
volumes of 12 litres a day should flush the tubular system
to keep it protected from damage by hyperuricosuria and/
or myoglobin [1]. Thus, rapid and aggressive therapeutic
intervention helps to prevent fatal complications like
arrhythmias, renal failure and disseminated vascular
coagulation [1,2,3,4].
Organelles and rhabdomyolysis
Central to all forms of rhabdomyolysis are decline in
intracellular ATP levels and elevation in myoplasmic
Ca2+ concentration (Figure 1) [6]. Thus, sufficient
ATP supply by mitochondrial respiratory chain fails
and as a consequence replenishing Ca2+ stores and extru-
sion of Ca2+ to the extracellular space is reduced. It is
assumed that these long-lasting Ca2+ elevations activate
calpain proteases, which further degrade proteins that
participate in Ca2+ homeostasis and thereby aggravate
myoplasmic Ca2+ overload, as has been shown for statins
[5,7]. This scenario is also corroborated by the finding
that the dihydropyridine nifedipine and the ryanodine
receptor blocker dantrolen are capable to attenuate exer-
cise and hyperthermia induced skeletal muscle damage
[6,8–10]. Additionally, the skeletal muscle specific cal-
pain 3 protease may contribute a further pathomechanism



















defects of lipid metabolism and fatty acid oxidation
deficiencies in succinate dehydrogenase, cytochrome
c oxidase, coenzyme Q10, myoadenylate deaminase,
glucose-6-P dehydrogenase, complex II and III
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Schematic presentation of a skeletal muscle cell. Diseases label the location and site of injury and defect. Sarcoplasmic reticulum (SR), the ryanodine
receptor (RyR), DHP receptor (the voltage sensitive L-Type Ca2+ channel) and sarcomeres (myocontractile machinery). During rhabdomyolysis
reduced myoplasmic ATP concentrations facilitate elevated Ca2+ concentrations.Calpain 3 is tethered to the giant protein titin, in particu-
lar to the N2A line and contributes to sarcomeric remo-
delling under physiological exercise [11].
Thus, mitochondria, sarcoplasmic reticulum and Ca2+
influx mechanisms, also besides excitation-contraction-
coupling contribute and take over in the development of
rhabdomyolysis.
Gene defects and rhabdomyolysis
Genetic polymorphisms and defects accounting for
skeletal muscle diseases potentiate the risk for episodes
of rhabdomyolysis (Figure 1). These defects include
enzymes from the glycolysis and glycogenolysis pathway
and pentose phosphate pathway. Impaired mitochondrial
pathways involve fatty acid oxidation, the citric acid cycle
and the mitochondrial respiratory chain [4]. And finally,
defects in the Ca2+ homeostasis are seen in patients with
mutations in proteins involved in excitation-contraction
coupling, myotonias and skeletal muscle dystrophies
[4,12].
This is exemplified by a case of a two year old patient with
recurrent hemolytic uremic syndrome and rhabdomyoly-
sis. The child is diagnosed for succinate coenzyme Q
reductase (complex II) deficiency, which is directly
linked to the Krebs cycle via succinate dehydrogenase
[13]. Hence, ATP depletion by a defect of oxidative
phosphorylation is likely to be causative in this individual
to trigger myotoxicity repetitively.Current Opinion in Pharmacology 2012, 12:335–339 Newly authorised drugs with risk of
rhabdomyolysis
The list of drugs that are reported to exert elevated risk
for rhabdomyolysis is very long and has been extensively
reviewed by others [3,4,12,14]. In particular, HMG-CoA
reductase inhibitors have a higher risk to generate
skeletal muscle side effects alone or in combination with
other drugs owing to interference on the level of uptake/
transport and metabolisation [5]. Therefore, I will focus
on novel compounds with recently described episodes of
rhabdomyolysis and their possible molecular targets.
Multitargeted tyrosine kinase inhibitors
The novel multitargeted tyrosine kinase inhibitor suni-
tinib is beneficial in overall survival of renal and colon
cancer patients and shows remarkable activity in a variety
of other tumor types even when given as a single agent
anti-cancer drug [15,16]. However, sunitinib is associated
with hypertension, left ventricular dysfunction and con-
gestive heart failure in up to 15% [16,17]. Human heart
biopsies and off-target screening has identified disruption
of the mitochondrial architecture and an IC50 for AMP-
kinase inhibition as low as 0.2 mM [18]. Thereby suni-
tinib interferes with fatty acid b-oxidation and glycogen-
olysis. The ATP concentration in sunitinib treated
cardiomyocytes is significantly reduced, which corrobo-
rates abnormalities in energy generation. Under these
conditions AMP-kinase activity acts as a rescue pathway
(Figure 2). Hence, inhibition by sunitinib is therefore
deleterious. Surprisingly, rhabdomyolysis has beenwww.sciencedirect.com
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Analogs to Figure 1 drugs label the site of action within a skeletal muscle cell to trigger rhabdomyolysis. Question marks indicate postulated targets.recently reported for sunitinib in two patients with meta-
static renal cell cancer receiving 37.5–50 mg sunitinib per
day for multiple cycles [19]. The two patients showed a
more than 50% reduction in left ventricular ejection
fraction and massive elevation of CK, myoglobinuria
leading to renal failure. Myocardial infarction could be
excluded and the diagnosis rhabdomyolysis was con-
cluded, although using a cut off limit for CK of 5 fold
above upper limit of normal.
Cardiac toxicity of tyrosine kinase inhibitors is
described for imatinib, dasatinib, nilotinib, sorafenib
and lapatinib [18,20,21]. Sorafenib enhances the preva-
lence for myositis, but rhabdomyolysis is not found
[22]. Interestingly, severe myotoxicity has not been
reported for the above mentioned kinase inhibitors,
except imatinib. In patients with chronic myelogenous
leukemia or gastrointestinal stromal tumors rhabdo-
myolysis has been confirmed for imatinib to be more
often then in other cohorts of patients [23]. However, a
molecular target for imatinib triggered myotoxicity has
not been identified [23,24].
The epidermal growth factor (EGF) receptor tyrosine
kinase inhibitor, erlotinib, has been shown to cause
rhabdomyolysis when combined with simvastatin. This
is obviously true to a CYP3A4 interaction of the two drugs
[25]. Importantly, one case of rhabdomyolysis is reported
from a non-small cell lung cancer patient receiving second
line erlotinib treatment (150 mg/day) [26]. In this patient
myotoxicity is attributable to erlotinib, however, a mol-
ecular target is unknown at the moment.www.sciencedirect.com Taken together, tyrosine kinase inhibitors exert cardio-
toxicity and myotoxicity, most probably by a common
target interaction.
Trabectedin
Approved in 2010, trabectedin represents a novel DNA-
binding anti-cancer drug effective in soft tissue sarcoma.
Severe cases of rhabdomyolysis have been reported
already throughout phase II studies [27–29]. The mech-
anism by which trabectedin elicits rhabdomyolysis is
unknown. Nevertheless, a positive correlation could be
established between rhabdomyolysis with the area under
the curve of trabectedin and elevated bilirubin levels [29].
Furthermore, elevated liver parameters precede rhabdo-
myolysis and reduced hepatic blood flow as it is seen
under beta adrenergic receptor blockade, which should be
avoided when trabectedin is applied. In fact, carvedilol
was concomitantly administrated with trabectedin in two
cases of rhabdomyolysis [27,29].
Leflunomide
Leflunomide represents a novel disease modifying anti-
rheumatic drug, which inhibits the mitochondrial dihy-
droorotate dehydrogenase and thereby the de novo pyr-
imidine synthesis [30,31]. The exceptional long half-life
of leflunomide, which is about 2–3 weeks, implicates long
lasting adverse effects even when the drug has been
discontinued. The spectrum of side effects involves
hypertension, transient hepatotoxicity, alopecia, gastro-
intestinal symptoms and also cutaneous adverse reactions.
Two cases of a more than 10 fold increase in CK are found
in the literature [30,31]. A mechanistic explanation for theCurrent Opinion in Pharmacology 2012, 12:335–339
338 Musculoskeletaldevelopment of rhabdomyolysis is pending, but from one
case a histological examination of a skeletal muscle biopsy
exists. Necrotic areas and infiltrations with inflammatory
mononuclear cells are documented. Again a molecular
target for this compound is not available and needs
further investigation to identify the cause of these rare
side effects of leflunomide [30].
Daptomycin
Daptomycin is the first approved cyclic lipopeptide with
bactericidal activity against Gram-positive bacteria [32].
Dosages above 8 mg/kg and an application interval shorter
than 24 h significantly enhance the risk for skeletal muscle
side effects, including rhabdomyolysis [33]. Interestingly,
cardiac muscle is not affected. In vitro, these observations
are confirmed in spontaneous contracting rat myoblasts and
myocytes. While undifferentiated myoblasts were resistant
to daptomycin induced injury up to concentrations of 6 mg/
ml, differentiated myocytes were damaged with 2 mg/ml.
Moreover, already 0.75 mg/ml daptomycin were sufficient
to suppress spontaneous contractility [34]. Thus, a break-
down of the membrane potential is most likely and could
be explained by the pore forming ability of daptomycin.
However, this does not explain the resistance of myoblasts
against the lipopeptide and the lack of effects in the heart.
In humans, CK is the proven and recommended marker to
monitor possible skeletal muscle side effects during dap-
tomycin application, given by the fact that myopathies
occur with a frequency of 0.2% [32,33]. Consequently, a
once daily application has been recommended to reduce
the risk for rhabdomyolysis [35–38]. Again, coadministra-
tion of HMG-CoA reductase inhibitors should be avoided,
because of the enhanced risk to develop rhabdomyolysis
and renal failure [39].
Propofol
For long propofol is widely used as a short acting anesthetic
and for sedation of critical ill patients up to several days.
Current recommendations suggest a dosage less than 8 mg/
kg/h and application not longer than 2 days in adults. Vasile
et al. have summarized 14 cases of propofol syndrome with
an average application duration of 86.1  42.9 h
(mean  S.D.) and a mean dosage of 8.7  3.6 mg/kg/h
[40]. Elevation of CK, myopathy and finally rhabdomyo-
lysis are often observed in this syndrome [40–42]. On
molecular level propofol is toxic for mitochondria and
elevates malonyl-carnitine levels. It uncouples the oxi-
dative phosphorylation, inhibits the respiratory chain at
complex II and most probably also at complex IV on the
level of cytochrome oxidase activity [43,44,45]. In particu-
lar, fatty acid transport is inhibited by elevated malonyl-
carnitine levels that thereby hamper the energy production
from catecholaminergic lipolysis [45].
Discussion
Rhabdomyolysis is a severe drug side effect, which occurs
also with novel drugs exemplified in this overview.Current Opinion in Pharmacology 2012, 12:335–339 However, a correlation of the symptoms with morphologi-
cal alterations has not yet been determined. Unfortunately,
the exact molecular mechanisms leading to this potentially
life threatening condition are diverse and still a matter of
debate especially for new drugs on the market. Report
systems are maintained by world health organisations to
facilitate registration of new adverse drug events. But then
it is difficult and time consuming to award domain experts
to detect further events in order to confirm a drug-induced
rhabdomyolysis.
Interestingly, a recent concept for in silico detection and
prediction of possible risk drugs for rhabdomyolysis was
introduced by Vilar et al. [46]. Fingerprinting new com-
pounds with drugs in a database with an already existing
hazard risk for rhabdomyolysis have improved prediction
and reduction of false positive hits for rhabdomyolysis.
Accordingly, these results strengthen the conjecture that
structural prerequisites are the crucial determinants for
the risk of rhabdomyolysis. Moreover, one can also draw
the conclusion that molecular switches have to exist that
propagate and support the development of rhabdomyo-
lysis, as shown for ATP production and Ca2+ homeostasis.
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